CML Publications 2021

CML publications 2021

Clinical Publications	Scientific Publications
December 2021
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients Breccia M et al. Expert Rev Hematol, December 2021 (epub ahead of print)	Shedding light on targeting chronic myeloid leukemia stem cells Houshmand M et al. J Clin Med, December 2021 – open access publication
Low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial Murai K et al. Lancet Haematol, December 2021	Antimetabolic cooperativity with the clinically approved L-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells Trinh A et al. Mol Metab, December 2021 – open access publication
Low-dose dasatinib: when less can be more Amrein PC. Lancet Haematol, December 2021	Description of PTPRG genetic variants identified in a cohort of chronic myeloid leukemia patients and their ability to influence response to tyrosine kinase inhibitors Ismail MA et al. Gene, December 2021 (epub ahead of print) – open access publication
Blast and accelerated phase CML: room for improvement How J et al. Hematology Am Soc Educ Program, December 2021 – open access publication	Quantitative proteomic analysis of plasma exosomes to identify the candidate biomarker of imatinib resistance in chronic myeloid leukemia patients Li MY et al. Front Oncol, December 2021 – open access publication
Matchpoint: the game is not over for blast-phase chronic myeloid leukemia Rousselot P. Lancet Hematol, December 2021 (epub ahead of print)	Large-scale topological disruption of chromosome territories 9 and 22 is associated with nonresponse to treatment in CML Fabian-Morales E et al. Int J Cancer, December 2021 (epub ahead of print) – open access publication
Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation – First case series from a single institution Young PE et al. Leuk Res, December 2021	Screening and identification of key genes in imatinib-resistant chronic myelogenous leukemia cells: a bioinformatics study Zhang H et al. Hematology, December 2021 – open access publication
TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission? Hochhaus A and Ernst T. Hematology Am Soc Hematol Educ Program, December 2021 - open access publication	Neutrophil extracellular traps are increased in chronic myeloid leukemia and are differently affected by tyrosine kinase inhibitors Telerman A et al. Cancers(Basel), December 2021 – open access publication
Lifelong TKI therapy: how to manage cardiovascular and other risks Mauro MJ. Hematology Am Soc Hematol Educ Program, December 2021 – open access publication	A bis-pyridinium fullerene derivative induces the generation of ROS in BCR-ABL-positive leukemia cells Sumi K et al. Eur J Pharmacol, December 2021 (epub ahead of print)
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-crisis chronic myeloid leukemia (MATCHPOINT): a single-arm, multicentre phase 1/2 trial Copland M et al. Lancet Haematology, December 2021 (epub ahead of print)	Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation Ding L et al. Eur J Pharmacol, December 2021
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive leukemias Kota V et al. Leuk Res, December 2021	SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment Egeli DB et al. Leuk Lymphoma, December 2021 (epub ahead of print)
Chronic myeloid leukemia stem cells targeting therapeutic implications Mojtahedi H et al. Stem Cell Res Ther, December 2021 – open access publication	The effect of Gö6976 on chronic myeloid leukemia in vitro and in vivo Cao ZR et al. Hematology, December 2021
BCR-ABL1 p210 screening for chronic myeloid leukemia in patients with peripheral blood cytoses Fenu E et al. Int J Lab Hematol, December 2021	Potential approaches versus approved or developing chronic myeloid leukemia therapy Andretta E et al. Front Oncol, December 2021 – open access publication
Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second-generation tyrosine kinase inhibitor to an alternative TKI Ma CE et al. Leuk Res, December 2021
Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series Bayrak AG et al. Leuk Res, December 2021
Second-generation tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia patients with stable deep molecular response: A systematic review and meta-analysis Di Q et al. Comput Math Methods Med, December 2021 – open access publication
November 2021
Droplet digital PCR for BCR-ABL1 monitoring in diagnostic routine: Ready to start? Bochiccio MT et al. Cancers (Basel), Oct 2021 – open access publication	Tnfrsf4-expressing regulatory T cells promote escape of chronic myeloid leukemia stem cells Hinterbrandner M et al. JCI Insight, November 2021 (epub ahead of print) – open access publication
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs Réa D et al. Blood, November 2021	Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR203/ABL1 and circ_0051886/miR-637/ABL1 Lu YH and Huang ZY. Mol Med, November 2021 – open access publication
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis Shoukier M et al. Haematologica, November 2021 – open access publication	Activated naïve gammadelta T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia Chang YY et al. Blood Cancer J, November 2021 – open access publication
Asciminib for CML: same target, new arrow Schiffer CA Blood, November 2021	MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common ß chain cytokine receptor endocytosis Zhao H et al. Blood, November 2021 (epub ahead of print)
Taming the gatekeeper: ponatinib dose holds the key Branford S Blood, November 2021	Age- and gender-independent association of XRCC1 polymorphism with chronic myeloid leukemia Abdalhabib EK Int J Gen Med, November 2021 – open access publication
Analyzing the impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia Santos FM et al. Am J Hematol, November 2021 (epub ahead of print) – open access publication	Salidroside inhibits chronic myeloid leukemia cell proliferation and induces apoptosis by regulating the miR-140-5p/wnt5a/beta-catenin axis Chen D and Luo C. Exp Ther Med, November 2021 – open access publication
Statins enhance the molecular response in chronic myeloid leukemia when combined with tyrosine kinase inhibitors Jang HJ Cancers (Basel), November 2021 (epub ahead of print)	Accurate machine-learning-based classification of leukemia from blood smear images Dese K et al. Clin Lymphoma Myeloma Leuk, November 2021
Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML Niederwieser C et al. Bone Marrow Transplant, November 2021 – open access publication	How to predict relapse in leukemia using time series data: A comparative in silicio study Hoffmann H et al. PLoSOne, November 2021 – open access publication
Asciminib as a new option in the treatment of chronic myeloid leukemia Ibis B ete al. Future Oncol, November 2021 (epub ahead of print)
Monitoring and improving adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia: A systematic review Tan BK et al. Patient Prefer Adherence, November 2021 – open access publication
Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the US Yue X et al. Leuk Lymphoma, November 2021 (epub ahead of print)
Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors Nakamae M et al. Int J Hematol, November 2021 (epub ahead of print)
A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML Webster JA et al. Leuk Res, November 2021 (epub ahead of print)
A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities Nekoukar Z et al. Blood Res, November 2021 (epub ahead of print) - open access publication
October 2021
Droplet digital PCR for BCR-ABL1 monitoring in diagnostic routine: Ready to start? Bochiccio MT et al. Cancers (Basel), Oct 2021 – open access publication	Investigation on the interaction behaviour of afatinib, dasatinib, and imatinib docked to the BCR-ABL protein Rocha KML eta l. J Mol Mode, October 2021
Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT Masouridi-Levrat S et al. Bone Marrow Transplant, October 2021 (epub ahead of print) – open access publication	Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers Krishnan V et a. Haematologica, October 2021 (epub ahead of print) – open access publication
Making treatment-free remission (TFR) easier in chronic myeloid leukemia: Fact checking and practical management tools Castagnetti F et al. Target Oncol, October 2021 (epub ahead of print) - open access publication	Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients Park H et al. Leuk Res, October 2021 (epub ahead of print)
Prediction of cardiovascular events in patients with chronic myeloid leukemia using baseline risk factors and coronary artery calcium scoring Baggio D et al. Intern Med J, October 2021	Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance Song T et al. Leukemia, October 2021
Imatinib plasma levels in patients with chronic myeloid leukemia under routine clinical practice conditions Del Rosario García B et al. J Oncol Pharm Pract, October 2021	JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signalling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia Aranda-Tavío H et al. Biomed Pharmacother, October 2021 (epub ahead of print)
Pharmacokinetics of asciminib when taken with imatinib or with food Hoch M et al. Clin Pharmacol Drug Dev, October 2021 (epub ahead of print)	3D tissue engineered plasma cultures support leukemic proliferation and induces drug-resistance Alhallah K et al. Leuk Lymphoma, October 2021
Treatment-free remission: the new goal in CML therapy Atallah E and Sweet K. Curr Hematol Malig Rep, October 2021 (epub ahead of print) – open access publication	Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance Wu YY et al. Cell Death Dis, October 2021 (open access publication)
The evolving landscape of frontline therapy in chronic phase chronic myeloid leukemia (CML) Wolfe HR and Rein LAM. Curr Hematol Malig Rep, October 2021 (epub ahead of print)
The cure of leukemia through the optimist’s prism Kantarjian HM et al. Cancer, October 2021 (epub ahead of print)
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia Malik S et al. Expert Rev Hematol, October 2021 (epub ahead of print)
Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: Current state and future directions Schoenbeck KL and Flynn KE. Curr Hematol Malig Rep, October 2021 (epub ahead of print)
Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia: Final report of the PhilosoPhi34 Study Pungolino E et al. Eur J Hematol, October 2021 – open access publication
Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and PH+ ALL Kawano N et al. Int J Hematol, October 2021
Which tyrosine kinase inhibitors should be selected as the first-line treatment for chronic myelogenous leukemia in chronic phase? Ono T. Cancers (Basel), October 2021 - open access publication
September 2021
Quality of life improvements in patients with chronic myeloid leukemia after stopping long-term therapy: who can benefit the most? Efficace F and Baccarani M. J Natl Cancer Inst, September 2021 (epub ahead of print) - open access publication	Genetic heterogeneity in chronic myeloid leukemia: How clonal hematopoiesis and clonal evolution may influence prognosis, treatment outcomes, and risk of cardiovascular events Sant’Antonio E et al. Clin Lymphoma Myeloma Leuk, September 2021
Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors Schoenbeck KL et al. J Natl Cancer Inst, September 2021 (epub ahead of print)	Granulocyt and monocytic myeloid-derived suppressor cells are functionally and prognostically different in patients with chronic myeloid leukemia Ahn A et al. Ann Lab Med, September 2021 – open access publication
Chronic myeloid leukemia: Modern therapies, current challenges and future directions Osman AEG and Deininger MW. Blood Rev, September 2021	Association of creatine elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study Bankar A and Lipton LH. Leuk Lymphoma, September 2021 (epub ahead of print)
Long-term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic-phase treated outside clinical trials: a real-life cohort observational study Stagno F et al. Acta Oncol, September 2021 (epub ahead of print)	Intracellular delivery of anti-BCR-ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells Jiang G et al. J Hematol Oncol, September 2021 – open access publication
Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: is there a real benefit? Canet J et al. Cancer Med, September 2021 (epub ahead of print) – open access publication	BCR-ABL1 transcript doubling time as a predictor for tre atment free remission after imatinib discontinuation in chronic myeloid leukemia Kim DDH et al. Br J Hematol, September 2021 (epub ahead of print)
Current evidence of the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs Erçaliskan A et al. Blood Adv, September 2021 - open access publication	Spred1 deficit promotes treatment resistance and transformation of chronic phase CML Qiao J et al. Leukemia, September 2021 (epub ahead of print)
How I treat chronic phase chronic myelogenous leukemia Berman E et al. Blood, September 2021 (epub ahead of print)	Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients Harada I et al. Sci Rep, September 2021 – open access publication
Chronic myeloid leukemia with pure erythroid leukemic blast crisis Jacobs JW et al. Leuk Lymphoma, September 2021 (epub ahead of print)	PKC-beta/Alox5 axis activation promotes BCR-ABL-independent TKI-resistance in chronic myeloid leukemia Ma D et al. J Cell Physiol, September 2021
Debating frontline therapy in chronic myeloid leukemia Bi X et al. Front Oncol, September 2021 – open access publication	Mitochondrial metabolism as a potential therapeutic target in myeloid leukemia de Breauchamp L et al. Leukemia, September 2021 (epub ahead of print) - open access publication
Nilotinib versus Imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroups of the randomized ENESTnd trial Nakamae H et al. Int J Hematol, September 2021 (epub ahead of print)
Response to tyrosine kinase inhibitors in real-world patients with chronic myeloid leukemia Szeto AH et al. Ann Pharmacother, September 2021 (epub ahead of print) – open access publication
Severe pleural effusion associated with nilotinib for chronic myeloid leukemia: cross-intolerance with tyrosine kinase inhibitors Satoh K et al. BMJ Case Rep, September 2021
August 2021
A phase 3, open-label, randomized study of Asciminib, a STAMP inhibitor, vs Bosutininb in CML after ≥ prior TKI’s Rea D et al. Blood, August 2021 (epub ahead of print)	ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cells Yang S et al. Blood, August 2021 (epub ahead of print)
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: A randomized, open-label phase 2 clinical trial Cortes J et al. Blood, August 2021 (epub ahead of print)	Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib msylate therapy Karasu N et al. Med Oncol, August 2021
Chronic myeloid leukemia Cortes J et al. Lancet, August 2021 (epub ahead of print)	Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question. Henry A et al. Br J Haematol, August 2021 (epub ahead of print) – open access publication
Inotuzumab ozoganicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia Jain N et al. Am J Hematol, August 2021	Molecular, cytogenetic, and haematological analysis of chronic myeloid leukemia patients and discovery of two novel translocations Asif M et al. Anal Cell Pathol (Amst), August 2021 – open access publication
Pulmonary hypertension in patients with chronic myeloid leukemia Song IC et al. Medicine (Baltimore), August 2021 – open access publication	CRISPR-Cas9 technology as a tool to target gene drivers in cancer: proof of concept and new opportunities to treat chronic myeloid leukemia Vuelta E et al. CRISPR J, August 2021
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged > 65 years resistant/intolerant to previous tyrosine-kinase inhibitors Latagliata R et al. Hematol Oncol, August 2021	Genomic copy number variants in CML patients with the Philadelphia chromosome (Ph+): An update Zhang H et al. Front Genet, August 2021 – open access publication
Extramedullary blast crisis in a chronic myeloid leukemia patient after achieving a major molecular response with bosutinib Nakajima R et al. Br J Haematol, August 2021 (epub ahead of print) – open access publication	From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia Thakral B et al. Ann Diagn Pathol, August 2021
Early prediction of stable MR(4.5) by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib Nee A et al. Leuk Lymphoma, August 2021 (epub ahead of print)	KIR3DL1 allotype-dependent modulations of NK cell immunity against chronic myeloid leukemia Izumi K et al. Immunohorizons, August 2021
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia Breccia et al. Expert Opion Investig Drugs, August 2021	MiR-150 expression in chronic myeloid leukemia: Relation to imatinib response Habib EM et al. Lab Med, August 2021 (epub ahead of print)
Is the Sokol or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors? Zhang XS et al. Leukemia, August 2021 (epub ahead of print) – open access publication	Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia Qing Y et al. Cell Commun Signal, August 2021 – open access publication
Tyrosine kinase inhibitor and vascular adverse events in chronic myeloid leukemia patients: a population-based, prospensity score-matched cohort study Chen MT et al. Oncologist, August 2021 (epub ahead of print) – open access publication
Long-term tolerability and efficacy after initial PegIFN- α addition to dasatinib in CML-CP – five year follow-up of the Nord CML007 study Flygt H et al. Eur J Haematol, August 2021 (epub ahead of print) – open access publication
Treatment free remission in patients with chronic myeloid leukemia: recommendations of LALNET expert panel Pavlovsky C et al. Blood Adv, August 2021 (epub ahead of print) - open access publication
Treatment-free remission in chronic myeloid leukemia: Can we identify prognostic factors? Scifullah HH and Lucas CM. Cancers (Basel), August 2021 – open access publication
July 2021
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukemia patients Rousselot P et al. Br J Haematol, July 2021	TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signalling Agarwal P et al. Cell Rep, July 2021 – open access publication
Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity Janssen L et al. Haematologica, July 2021 – open access publication	ND-09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR-ABL signalling Liu YH et al. Oncol Rep, July 2021 – open access publication
Ophthalmologic manifestations as the initial presentation of chronic myeloid leukemia: A Review Yassin MA et al. Surv Ophthalmol, July 2021 (epub ahead of print) – open access publication	Role of lysophospholipid metabolism in chronic myelogenous leukemia stem cells Naka K. Cancers(Basel), July 2021 – open access publication
Arterial hypertension assessment in a population with chronic myeloid leukemia Roa-Chamorro R et al. Sci Rep, July 2021 – open access publication	DNA methylation and intra-clonal heterogeneity: The chronic myeloid leukemia model Lebecque B et al. Cancers(Basel), July 2021 – open access publication
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia in tyrosine kinase inhibitors Rodia R et al. J Endocrinol Invest, July 2021 (epub ahead of print) – open access publication	HNRNPH1 is a novel regulator of cellular proliferation and disease progression in chronic myeloid leukemia Liu M et al. Front Oncol, July 2021 – open access publication
Efficacy and cardiovascular adverse events of long-term treatment with tyrosine kinase inhibitors for chronic myeloid leukemia: A Report from the Nagasaki CML Study Group Chiwata M et al. Intern Med, July 2021 – open access publication	Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation and changes following interferon treatment Kong J et al. Ann Hematol, July 2021 (epub ahead of print)
Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs. imatinib among patients with chronic myeloid leukemia: A systematic review and meta-analysis Wang Z et al. JAMA Netw open, July 2021 – open access publication	Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukemia at diagnosis and early follow-up Romzova M et al. Br J Haematol, July 2021 (epub ahead of print)
Impact of BCR-ABL1 transcript type on response, treatment-free remission rate and survival in chronic myeloid leukemia patients treated with imatinib Marcé S et al. J Clin Med, July 2021 – open access publication
Quality of life among chronic myeloid leukemia patients in the second line treatment with nilotinib and influential factors Nguyen CTT et al. Quali Life Res, July 2021 (epub ahead of print)
Correlates of fatigue severity in patients with chronic myeloid leukemia treated with targeted therapy Oswald LB et al. Support Care Cancer, July 2021 (epub ahead of print)
June 2021
Impact of frontline treatment approach on outcome of myeloid blast phase CML Saxena K et al. J Hematol Oncol, June 2021 – open access publication	Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia Shindo T et al. Immunol Med, June 2021
Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy Cortes J et al. Eur J Haematol, June 2021 – open access publication	Gata2-L359V impairs primitive and definitive hematopoiesis nd blocks cell differentiation in murine chronic myelogenous leukemia models Fu YK et al. Cell Death Dis, June 2021 – open access publication
Measuring prognosis in chronic myeloid leukemia: What’s new? Breccia M et al. Expert Rev Hematol, June 2021 (epub ahead of print)	Zfp36I1 plays an ambiguous role in the regulation of cell expansion and negatively regulates Cdkn1a in chronic myeloid leukemia cells Kaehler M et al. Exp Hematol, June 2021 (epub ahead of print)
Treatment-free remission of chronic myeloid leukemia in real-world practice by the detected limit of MR4.3 Park P et al. Leuk Res, June 2021	Cytochrome P4502C19 gene polymorphisms (CYP2C192 and CYP2C193) in chronic myeloid leukemia patients: in vitro and in silico studies Joshi K et al. J Biomol Struct Dyn, June 2021 (epub ahead of print)
Appropriate starting does of dasatinib based on analyses of dose-limiting toxicities and molecular responses in Asian patients with chronic myeloid leukemia Shin H et al. Clin Lymphoma Myeloma Leuk, June 2021	Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukemia: mass spectrometry versus next generation sequencing Shanmunagathan N and Branford S. Br J Haematol, June 2021 (epub ahead of print)
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia Breccia M et al. Expert Opin Investig Drugs, June 2021 (epub ahead of print)	Metabolic alterations mediated by STAT3 promotes drug persistence in CML Patel SB et al. Leukemia, June 2021 (epub ahead of print) - open access publication
Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience Ureshino H et al. Hematol Oncol, June 2021 (epub ahead of print)	CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells Kim JH et al. Biochem Pharmacol, June 2021 (epub ahead of print)
Successful tyrosine kinase inhibitor discontinuation outside clinical trials – data from the population-based Swedish CML Registry Flygt H et al. Br J Haematol, June 2021 – open access publication	Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukemia in an International interlaboratory study Scott S et al. Br J Haematol, June 2021 (epub ahead of print) – open access publication
Pharmakokinetics of Asciminib in individuals with hepatic or renal impairment Hoch M et al. J Clin Pharmacol, June 2021 (epub ahead of print)	Positive interactions between STAP1 and BCR-ABL influences chronic myeloid leukemia cell proliferation and survival Ishiura M et al. Biochem Biophys Res Comm, June 2021
Perspectives and emotional experiences of patients with chronic myeloid leukemia during ENESTPath clinical trial and treatment-free remission: Rationale and protocol of the Italian substudy Borghi L et al. Front Oncol, May 2021 – open access publication	Targeting FEN1 suppresses the proliferation of chronic myeloid leukemia cells through regulating alternative end-joining pathways Zhu Y et al. DNA Cell Biol, June 2021 (epub ahead of print)
Review of new-generation tyrosine kinase inhibitors for chronic myeloid leukemia Shoukier M et al. Curr Oncol Rep, June 2021	Brefeldin A induces apoptosis, inhibits BCR-ABL activation, and triggers BCR-ABL degradation in CML K562 cells Zhang JM et al. Anticancer Agents Med Chem, June 2021 (epub ahead of print)
Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia: final report of the PhilosoPhi34 study Pungolino E et al. Eur J Haematol, June 2021 (epub ahead of print)	Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells Liu Z et al. Exp Cell Res, June 2021 (epub ahead of print)
May 2021
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib. ENESTop 5-year update Hughes TP et al. Leukemia, May 2021 (epub ahead of print)	Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemic Lee H et al. Int J Hematol, May 2021
Why chronic myeloid leukemia cannot be cured by tyrosine kinase inhibitors Baccarani M and Gale RP. Leukemia, May 2021 (epub ahead of print)	Suppression of USP1 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis Jiang S et al. Cell Death Dis, May 2021 – open access publication
EUTOS long-term survival score discriminated different SOKAL score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study Breccia M et al. Leukemia, May 2021 (epub ahead of print)	Mutational landscape of chronic myeloid leukemia: more than a single oncogene Adnan-Awad S et al. Leuk Lymphoma, May 2021 (epub ahead of print)
Budget impact of tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia with sustained deep molecular response Astruge C et al. Value Health, May 2021	Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review Torres-Barrera P et al. Curr Res Transl Med, May 2021 (epub ahead of print)
Relevance of treatment-free remission recommendations in chronic phase chronic myeloid leukemia patients treated with frontline tyrosine kinase inhibitors Etienne G et al. Cancer Med, May 2021 (epub ahead of print) – open access publication	Validation of CIP2A as a biomarker of subsequent disease progression and treatment failure in chronic myeloid leukemia Clark RE et al. Cancers(Basel), May 2021 – open access publication
Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients Folta A et al. Leuk Lymphoma, May 2021	Clonal evolution and clinical implications of genetic abnormalities in blastic transformation in chronic myeloid leukemia Ochi Y et al. Nat Commun, May 2021 – open access publication
Promyelocytic blast phase of chronic myeloid leukemia; BCR-ABL1 positive: Points to be considered at diagnosis Kim B et al. Ann Lab Med, May 2021 – open access publication	Sirtuin1 and chronic myeloid leukemia: A comprehensive glance of drug resistance Abbasian S et al. Clin Lab, May 2021
Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: A real-world analysis of health plan enrolees Chow EJ et al. Leuk Lymphoma, May 2021
An indirect comparison between bosutinib, nilotinib and dasatinib in chronic phase chronic myeloid leukemia Muresan B et al. Curr Med Res Opin, May 2021 (epub ahead of print)
Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib Hall KH et al. Am J Hematol, May 2021 (epub ahead of print) – open access publication
Current status and novel strategy for CML Morita K and Sasaki K. Int J Hematol, May 2021
April 2021
Asciminib in chronic myeloid leukemia: Many questions still remain to be answered Eskazan AE. Blood Cancer J, April 2021 – open access publication	Recent advances in understanding chronic myeloid leukemia: Where do we stand? Kumar R and Krause DS. Fac Rev, April 2021 – open access publication
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib Morita K et al. Cancer, April 2021 (epub ahead of print)	Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape Hsieh YC et al. Leukemia, April 2021 (epub ahead of print) – open access publication
Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population based study Jamy O et al. Am J Hematol, April 2021 (epub ahead of print) - open access publication	Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy Schoepf AM et al. Eur J Med Chem, April 2021 – open access publication
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial Kim DDH et al. Br J Haematol, April 2021 (epub ahead of print)	An aging mouse model of human chronic myeloid leukemia Hao T et al. Oncogene, April 2021 (epub ahead of print)
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial Chuah C et al. Int J Hematol, April 2021 (epub ahead of print)	Repositioning antispasmodic drug papaverine for the treatment of chronic myeloid leukemia Parcha PK et al. Pharmacol Rep, April 2021
Bosutinib-related pleural effusion in patients with chronic myeloid leukemia Yüzbasloglu MB and Eskazan AE. Expert Opin Drug Saf, April 2021	The regulation of bcr-abl in hypoxia is through the mTOR pathway Clapper E et al. Leuk Lymphoma, April 2021
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up Scalzulli E et al. Leuk Lymphoma, April 2021	Leukemic stem cells shall be searched in the bone marrow before tyrosine kinase inhibitor-discontinuation in chronic myeloid leukemia Ilhan O et al. Int J Lab Hematol, April 2021 (epub ahead of print)
When to stop TKIs in patients with chronic myeloid leukemia and how to follow them subsequently Cerveira N et al. Curr Treat Options Oncol, April 2021	Rare monosomy 7 and deletion 7p at diagnosis of chronic myeloid leukemia in accelerated phase Alswied A et al. Cancer Genet, April 2021
Interventions to improve adherence to tyrosine kinase inhibitors in chronic myeloid leukemia: A systematic review Heiney SP et al. Am J Clin Oncol, April 2021 (epub ahead of print)
March 2021
Dosing strategies for improving the risk-benefit profile of ponatinib in patients with chronic myeloid leukemia in chronic phase Castagnetti F et al. Front Oncol, March 2021 – open access publication	Targeting chronic myeloid leukemia stem/progenitor cells using Venetoclax-loaded immunoliposome Houshmand M et al Cancers(Basel), March 2021 – open access publication
Third-line therapy for chronic myeloid leukemia: Current status and future directions Cortes J and Lang F. J Hematol Oncol, March 2021 – open access publication	Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study Ottmann OG et al. Leuk Lymphoma, March 2021
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial Radich JP et al. Leukemia, March 2021 (epub ahead of print) – open access publication	Treatment-free remission and immunity in chronic myeloid leukemia Ureshino H. Int J Hematol, March 2021 (epub ahead of print)
Asessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network Schäfer V et al. J Cancer Res Clin Oncol, March 2021 (epub ahead of print) – open access publication	New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism Naka K. Int J Hematol, March 2021 (epub ahead of print)
Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates Atallah EL et al. Leuk Lymphoma, March 2021 (epub ahead of print)	Efficiency of nilotinib to target chronic-phase chronic myeloid leukaemia primary mature CD34- and immature CD34+ cells Berger MG et al. Sci Rep, March 2021 – open access publication
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study Martínez-López J et al. Leuk Lymphoma, March 2021 (epub ahead of print)	The discovery of novel BCR-ABL tyrosine kinase inhibitors using a pharmacophore modelling and virtual screening approach Huang TT et al. Front Cell Dev Biol, March 2021 – open access publication
I rock the boat? When to stop TKI’s in CML? Nazha A. Blood, March 2021	Discovery of a novel CIP2A variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias Makela E et al. Clin Cancer Res, March 2021 (epub ahead of print) – open access publication
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience Pepe S et al. Leuk Lymphoma, March 2021 (epub ahead of print)	Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogeneic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B Bencome-Alvarez AE, Oncogene, March 2021 (epub ahead of print) – open access publication
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world setting in France: The POST-PACE study Etienne G et al. Leuk Res, March 2021 (epub ahead of print)	Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of CML progression Sloma I et al. Haematologica, March 2021 – open access publication
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients Scalzulli E et al. Ann Hematol, March 2021 (epub ahead of print)
arly BCR-ABL kinetics are predictive of subsequent achievement of treatment-free-remission in CML Shanmunagathan N et al. Blood, March 2021
February 2021
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKI’s: First interim analysis of OPTkIMA study Malagola M et al. Cancer Med, February 2021 (epub ahead of print) - open access publication	Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression Clark RE et al. Blood Adv, February 2021 - open access publication
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR – final report from AFTER-SKI Richter J et al. Leukemia, February 2021 (epub ahead of print) – open access publication	Eradicating residual chronic myeloid leukemia: basic research lost in translation Zhao H and Deininger M. Lancet Haematol, February 2021
Mortality rates in patients with chronic myeloid leukemia in chronic phase with frontline second generation kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA) Breccia M et al. Ann Hematol, February 2021	Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFTM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib Hrdinova T et al. Int J Oncol, February 2021
Dose-optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: A new therapeutic challenge Iurlo A et al. J Clin Med, February 2021 – open access publication	Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells Ozkan T et al. Leuk Res, February 2021 (epub ahead of print)
Bosutinib in the real-life treatment of chronic myeloid leukemia patients >65 years resistant/intolerant to previous tyrosine-kinase inhibitors Latagliata R et al. Hematol Oncol, February 2021 (epub ahead of print)	Circulating miR-1461 expression to imatinib in adult chronic myeloid leukemia Habib EM et al. J Investig Med, February 2021
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice Garcia-Gutiérrez V et al. Blood Cancer J, February 2021 – open access publication	Future approaches for treating chronic myeloid leukemia: CRISP therapy Vuelta E et al. Biology(Basel), February 2021 – open access publication
MR4 log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial Seguro FS et al. Leuk Res, February 2021	Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells Yahata T et al. Haematologica, February 2021 – open access publication
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors Efficace F et al. Expert Rev Hematol, February 2021 (epub ahead of print)	Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: is there a correlation? Frikha R et al. J Oncol Pharm Pract, February 2021 (epub ahead of print)
ong-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy Cortes JE et al. Eur J Haematol, February 2021 (epub ahead of print)	The prognostic importance of BCR-ABL transcripts in chronic myeloid leukemia: A systematic review and meta-analysis Ghalesardi OK et al. Leuk Res, February 2021
	Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML) Lu T et al. Eur J Pharmacol, February 2021 (epub ahead of print)
January 2021
Clinical outcomes of patients with chronic myeloid leukemia with concurrent core binding factor rearrangement and Philadelphia chromosome Morita K et al. Clin Lymphoma Myeloma Leuk, January 2021 (epub ahead of print)	The giant HECT E3 ubiquitin ligase HERC1 is aberrantly expressed in myeloid related disorders and it is a novel BCR-ABL1 binding partner Ali MS et al. Cancers(Basel), January 2021 – open access publication
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed CML in chronic phase: ENESTnd 10-year analysis Kantarjian HM et al. Leukemia, January 2021 (epub ahead of print) – open access publication	Genetic screening for potential new targets in chronic myeloid leukemia based on Drosophia Transgenic for human BCR-ABL Lo Iacono M et al. Cancers(Basel), January 2021 – open access publication
I Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukemia: results from the French SPIRIT phase III randomised trial Guilhot F et al. Leukemia, January 2021 (epub ehead of print)	The quiescent fraction of chronic myeloid leukemia stem cells depends on BMPR1B, STAT3, and BMP4-niche signals to persistent in patients in remission Jeanpierre S et al. Haematologica, January 2021 – open access publication
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice? Colafigli G et al. Crit Rev Oncol Hematol, January 2021	HLA polymorphis are associated with treatment-free re mission following discontinuation of TKI’s in CML Ureshino H et al. Mol Cancer Ther, January 2021
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia in patients treated with nilotinib Caocci G et al. Ann Hematol, January 2021 (epub ahead of print)	Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTor pathway in combination with TKIs: A review Singh P et al. Med Oncol, January 2021
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data Gambarcoti-Passerini C et al. Eur J Haematol, January 2021 – open access publication	The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration Ito F et al. Int J Hematol, January 2021
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real-life Santoleri F et al. Curr Med Res Opin, January 2021 (epub ahead of print)	NT157, an IGF1R-IRS1/2 inhibitor exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia Scopim-Ribeiro R et al. Invest New Drugs, January 2021 (epub ahead of print)
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukemia in the United Kingdom: the UK TARGET CML study Milojkociv D et al. Br J Haematol, January 2021 – open access publication
BCR-ABL kinase domain mutation analysis by Next Generation Sequencing detected additional mutations in CML patients with suboptimal response to Nilotinib Benjamin ESB et al. Leuk Lymphoma, January 2021 (epub ehead of print)

Translate page

iCMLf

Case Discussion Forums

iCMLf Prizes

Programs

Virtual Education Program

Presentations from the EHA2022 Congress

Our Global Presence

CML Publications 2021

CML publications 2021

EU e-Privacy Directive

COVID-19 Hub

Our Board of Directors

EU e-Privacy Directive